Dr. Petrylak on FDA Approval of Pembrolizumab in Bladder Cancer

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of patients with bladder cancer.

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of patients with bladder cancer.

Related Content:

Yale Cancer CenterOncLive TVImmuno-OncologyGenitourinary CancersImmunotherapy in GU Cancers
Dr Pant on the Importance of Targeted Therapy and Mutation Testing in Pancreatic Cancer
Dr Ecker on the Role of CAPETEM in the Treatment of Pancreatic NETs
Dr Garmezy on Findings From the Duravelo-1 Trial in Metastatic Urothelial Carcinoma